{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:55:41Z","timestamp":1794970541494,"version":"4.9.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>CD19 chimeric antigen receptor (CAR) T-cell therapy has proven highly effective for treating\u00a0relapsed\/refractory mantle cell lymphoma (MCL). However, immune effector cell\u2013associated neurotoxicity syndrome (ICANS) remains a significant concern. This study aimed to evaluate the clinical, radiological, and laboratory correlatives associated with ICANS development after CD19 CAR T-cell therapy in patients with MCL. All patients (N\u00a0= 26) who received standard-of-care brexucabtagene autoleucel until July 2022 at our institution were evaluated. Laboratory and radiographic correlatives including brain magnetic resonance imaging (MRI) and electroencephalogram (EEG) were evaluated to determine the clinical impact of ICANS. Seventeen (65%) patients experienced ICANS after treatment, with a median onset on day 6. Ten (38%) patients experienced severe (grade \u22653) ICANS. All patients with ICANS had antecedent cytokine release syndrome (CRS), but no correlation was observed between ICANS severity and CRS grade. Overall, 92% of EEGs revealed interictal changes; no patients experienced frank seizures because of ICANS. In total, 86% of patients with severe ICANS with postinfusion brain MRIs demonstrated acute neuroimaging findings not seen on pretreatment MRI. Severe ICANS was also associated with higher rates of cytopenia, coagulopathy, increased cumulative steroid exposure, and prolonged hospitalization. However, severe ICANS did not affect treatment outcomes of patients with MCL. Severe ICANS is frequently associated with a range of postinfusion brain MRI changes and abnormal EEG findings. Longer hospitalization was observed in patients with severe ICANS, especially those with abnormal acute MRI or EEG findings, but there was no discernible impact on overall treatment response and survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011896","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T20:01:56Z","timestamp":1706731316000},"page":"1474-1486","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-5905","authenticated-orcid":false,"given":"Esther H.","family":"Nie","sequence":"first","affiliation":[{"name":"1Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8372-1166","authenticated-orcid":false,"given":"Yi-Jiun","family":"Su","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"3Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-6546","authenticated-orcid":false,"given":"John H.","family":"Baird","sequence":"additional","affiliation":[{"name":"4Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-0381","authenticated-orcid":false,"given":"Melody","family":"Smith","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May H.","family":"Han","sequence":"additional","affiliation":[{"name":"1Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-6081","authenticated-orcid":false,"given":"Jeffrey E.","family":"Dunn","sequence":"additional","affiliation":[{"name":"1Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5464","authenticated-orcid":false,"given":"Lucas B.","family":"Kipp","sequence":"additional","affiliation":[{"name":"1Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5865-0327","authenticated-orcid":false,"given":"Brian J.","family":"Scott","sequence":"additional","affiliation":[{"name":"6Division of Neurohospitalist Medicine, Department of Neurology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"},{"name":"5Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"6","key":"2024032513152984800_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2024032513152984800_bib2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"2024032513152984800_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024032513152984800_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10299","key":"2024032513152984800_bib5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2024032513152984800_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"10343","key":"2024032513152984800_bib7","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"2024032513152984800_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"2024032513152984800_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024032513152984800_bib10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024032513152984800_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"2024032513152984800_bib12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024032513152984800_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024032513152984800_bib14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"2024032513152984800_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024032513152984800_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"27","key":"2024032513152984800_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024032513152984800_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jtct.2022.08.002","article-title":"Perspective: an international fludarabine shortage: supply chain issues impacting transplantation and immune effector cell therapy delivery","volume":"28","author":"Maziarz","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"2024032513152984800_bib19","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2024032513152984800_bib37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024032513152984800_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2022008031","article-title":"CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse","volume":"7","author":"Vu","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2024032513152984800_bib21","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024032513152984800_bib22","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"2024032513152984800_bib23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"issue":"12","key":"2024032513152984800_bib24","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"27","key":"2024032513152984800_bib25","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024032513152984800_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"2024032513152984800_bib27","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2024032513152984800_bib28","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"2024032513152984800_bib29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","article-title":"GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients","volume":"7","author":"Gust","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2024032513152984800_bib30","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2024032513152984800_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2021-150431","article-title":"A\u00a0phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T\u00a0cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024032513152984800_bib32","doi-asserted-by":"crossref","first-page":"10350","DOI":"10.1182\/blood-2022-169382","article-title":"JAK1 inhibition during CAR T-cell treatment does not affect CAR T-cell proliferation, persistence, or function","volume":"140","author":"Pratta","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024032513152984800_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2024032513152984800_bib34","doi-asserted-by":"crossref","first-page":"e005956","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"S2","key":"2024032513152984800_bib35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hon.3196_LBA3","article-title":"Lisocabtagene maraleucel (LISO-CEL) in R\/R MCL: primary analysis results from the MCL Cohort of the Single-Arm, Multicenter, Seamless Design TRANSCEND NHL 001 Study","volume":"41","author":"Wang","year":"2023","journal-title":"Hematol Oncol"},{"issue":"2","key":"2024032513152984800_bib36","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S2666-6367(23)00109-4","article-title":"40 - Results from a phase 1\/2 study of tandem, bispecific anti-CD20\/anti-CD19 (LV20.19) CAR T-cells for mantle cell lymphoma","volume":"29","author":"Shah","year":"2023","journal-title":"Transplantation and Cellular Therapy"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1474\/2219056\/blooda_adv-2023-011896-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1474\/2219056\/blooda_adv-2023-011896-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:16:10Z","timestamp":1711372570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/6\/1474\/514789\/Clinical-features-of-neurotoxicity-after-CD19-CAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011896","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}